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Abstract
17b-estradiol (E2) regulates hormonal release as well as proliferation and cell death in the pituitary. The main nitric oxide
receptor, nitric oxide sensitive- or soluble guanylyl cyclase (sGC), is a heterodimer composed of two subunits, a and b, that
catalyses cGMP formation. a1b1 is the most abundant and widely expressed heterodimer, showing the greater activity.
Previously we have shown that E2 decreased sGC activity but exerts opposite effects on sGC subunits increasing a1 and
decreasing b1 mRNA and protein levels. In the present work we investigate the mechanisms by which E2 differentially
regulates sGC subunits’ expression on rat anterior pituitary gland. Experiments were performed on primary cultures of
anterior pituitary cells from adult female Wistar rats at random stages of estrous cycle. After 6 h of E2 treatment, a1 mRNA
and protein expression is increased while b1 levels are down-regulated. E2 effects on sGC expression are partially
dependent on de novo transcription while de novo translation is fully required. E2 treatment decreased HuR mRNA
stabilization factor and increased AUF1 p37 mRNA destabilization factor. E2-elicited b1 mRNA decrease correlates with a
mRNA destabilization environment in the anterior pituitary gland. On the other hand, after 6 h of treatment, E2-BSA (1 nM)
and E2-dendrimer conjugate (EDC, 1 nM) were unable to modify a1o rb1 mRNA levels, showing that nuclear receptor is
involved in E2 actions. However, at earlier times (3 h), 1 nM EDC causes a transient decrease of a1 in a PI3k-dependent
fashion. Our results show for the first time that E2 is able to exert opposite actions in the anterior pituitary gland, depending
on the activation of classical or non-classical pathways. Thus, E2 can also modify sGC expression through membrane-
initiated signals bringing to light a new point of regulation in NO/sGC pathway.
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Introduction
Nitric oxide sensitive- or soluble guanylyl cyclase (sGC), the
main intracellular receptor of nitric oxide is comprised of two
subunits, a and b, of which several isoforms (a1, a2, a2i, b1 and
b2) have been described. a1b1 is the most abundant and widely
expressed heterodimer, showing the greater activity [1].
The major female hormone, 17b-estradiol (E2), is a key
regulator of pituitary physiology involved in hormonal release as
well as proliferation and cell death in anterior pituitary gland [2–
4].
Previous studies from our laboratory show that acute E2
treatment exerts an inhibitory effect on sGC activity by down-
regulating sGC b1 subunit in anterior pituitary gland. However,
this treatment increases sGC a1 expression from both, immature
and adult rats [5,6]. The E2 effects on anterior pituitary sGC were
observed not only after in vivo and in vitro treatment but also during
estrous cycle. These observations support a direct effect of E2 on
sGC regulation and a differential and independent regulation on
both subunits. Previous evidence [7–9] further sustains that under
certain conditions, a1 and b1 can be independently expressed.
E2 signaling pathways comprise classical and non-classical
actions. Classical actions are mediated by nuclear E2 receptor
(ER) and include both de novo transcriptional and translational
events. E2 non-classical actions are mediated by non-nuclear ER
and include the activation of signaling pathways that finally can
also trigger transcription of certain genes [10,11]. In many cells,
around 5–10% of total ER is found at the plasma membrane,
including both a and b ER subtypes depending on cell type [11].
E2 can also regulate many genes post-transcriptionally by
affecting mRNA stability. Certain mRNAs have highly conserved
sequences, adenine-uracil rich elements (AREs), present on
untranslated 39 end. AREs are involved in rapid mRNA
degradation and are binding targets of several proteins. They
constitute an important regulatory element involved in the control
of genetic expression in vertebrates. Human antigen-R RNA
binding protein (HuR) is ubiquitously expressed and belongs to
embryonic lethal abnormal vision (ELAV) family proteins. HuR
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HuR is of major relevance since it can stabilize inducible nitric
oxide synthase mRNA [13] and its expression seems to be directly
related to ARE-containing mRNAs stability [14–17]. sGC a1 and
b1 mRNAs include ARE sequences and both are able to bind
HuR [18]. AREs elements are also a target of other factors such as
heterogeneous nuclear ribonucleoprotein D (hnRNP D) also
known as A+U-rich binding factor 1 (AUF1). This protein through
competition with HuR regulates target mRNAs half-life and
degradation [19]. The family of AUF1 proteins appears to be able
to confer either stability or instability to target mRNAs, an effect
being cell type and AUF1 isoform-dependent [20]. It has been
previously shown that AUF1 expression is up-regulated by E2 in
uterus [21,22] and thus, can regulate the half-life of specific
mRNAs [23]. Besides, it has been demonstrated that AUF1 binds
sGC a2 mRNA in brain, which in turn decreases its half-life [24].
Taking into account this background we investigate whether E2
effect on sGC subunits is mediated through nuclear ER and/or
non-nuclear ER and its mechanisms of action in anterior pituitary
gland from adult female rats. Our results show a dual effect of E2
on sGC subunits expression depending on the activated ER
pathway. E2 acting through non-nuclear ER, in a PI3K-
dependent way, decreased a1 expression while acting through
nuclear ER up-regulated a1 levels. On the other hand, sGC b1
subunit expression was also affected by E2 but apparently only
through nuclear ER pathway. E2 actions on sGC mRNA levels
through nuclear ER were dependent on de novo transcription and de
novo translation, promoting an AREs-containing mRNAs destabi-
lization environment. Altogether, our results provide the first
evidence that E2 triggers opposite effects on sGC subunits
expression through classical and non-classical pathways in anterior
pituitary gland.
Results
E2 affects sGC subunits expression through both, nuclear
and non-nuclear ER in an opposite way
Previously we have shown that E2 effects on sGC subunits occur
specifically through ER [5]. To investigate which kind of ER is
involved in such effect, anterior pituitary cell cultures were
incubated with membrane-impermeable E2 compounds: bovine
serum albumin-conjugated E2 (E2-BSA) and estrogen dendrimer
conjugate (EDC) [25] using the free steroid (E2) as control. First
we studied the effect of E2-BSA on a1 and b1 mRNA levels after
6 h of treatment, the same time previously assayed [6]. Our results
show that 1 nM E2-BSA was unable to reproduce 1 nM free E2
effects on sGC subunits mRNA expression at the same
concentration (Figure 1). At the same time period and similarly
to E2-BSA effects, EDC could not reproduce E2 effects and a1
and b1 mRNA levels remained similar to control values (data not
shown). EDC neither modified a1o rb1 protein expression
(Figure 2) which further confirms that 6 h E2 treatment affects
sGC subunits expression mainly through nuclear ER.
Since the effects through non-nuclear ER take place at short
times after E2 administration we studied the effect of E2 on
subunits expression after 3 h of treatment and examined whether
they are mediated through non-nuclear ER. As shown in
Figures 3A and 4A and in agreement with previous report [6],
free E2 increased a1 and decreased b1 mRNA and protein
expression. Unexpectedly, at this time, EDC significantly de-
creased a1 mRNA and protein expression (Figure 3A and 4A,
respectively), an effect opposite to that seen after 3 h and 6 h of
free E2 incubation (Figure 2). Conversely, EDC did not
significantly modify b1 mRNA or protein expression after 3 h
(Figure 3A and 4A). At earlier times of treatment (1 h and 2 h)
neither free E2 nor EDC were able to modify a1o rb1 mRNA
expression (data not shown).
These results show that E2 affects sGC a1 and b1 expression
through both, non-nuclear and nuclear ER pathways in anterior
pituitary cells and displays different actions depending on the
pathway involved.
Figure 1. E2 actions on sGC a1 and b1 mRNAs were mediated
by nuclear ER after 6 h of incubation. Pituitary cells in culture were
incubated with vehicle (control) or 1 nM E2 or with 1 nM E2-conjugated
to BSA (E2-BSA) unable to trespass cell membrane during 6 h. sGC a1
and b1 mRNAs were evaluated by PCR. Top, a representative PCR.
Bottom, average densitometric values. Bars represent mean 6 SE of
relative units, corresponding to a1 (open bars) and b1 (black bars)
densitometric values normalized to b-actin, and are expressed as
percent of the control (n=3). ANOVA followed by Tukey’s test, *P,0.05,
**P,0.01 vs. respective controls.
doi:10.1371/journal.pone.0029402.g001
Figure 2. E2 actions on sGC a1 and b1 proteins were mediated
by nuclear ER after 6 h of incubation. Pituitary cells in culture were
incubated for 6 h with vehicle (control) 1 nM E2 or with 1 nM estrogen
dendrimer conjugate (EDC) unable to trespass cell membrane, or with
1 nM dendrimer alone (D). sGC a1 and b1 proteins were evaluated by
western blot. Top, a representative western blot. Bottom, average
densitometric values. Bars represent mean 6 SE of relative units
corresponding to a1 (open bars) and b1 (black bars) densitometric
values normalized to b-actin, and are expressed as percent of the
control (n=3). ANOVA followed by Tukey’s test, *P,0.05 vs. respective
controls.
doi:10.1371/journal.pone.0029402.g002
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nuclear ER
One of the first steps starting upon union of ligand to
extranuclear ER is the activation of phosphoinositide 3-kinase
(PI3K) [26]. To further confirm that E2 is acting through non-
nuclear ER, cells were co-incubated with EDC and 50 mM
LY294002 (LY), a specific inhibitor of PI3K. Results show that LY
had no effect by itself on sGC subunits expression. LY completely
blocked EDC actions on sGC a1 subunit expression at both,
mRNA and protein levels, while did not modify sGC b1 subunit
expression as compared with EDC effects (Figures 3B and 4B).
Altogether, these results suggest that E2 modifies sGC expression
through both nuclear and non-nuclear ER pathways. Activation of
non-nuclear ER-initiated, PI3k-dependent pathway transiently
decreases sGC a1 subunit. This effect is completely opposite when
E2 acts through nuclear ER signaling pathway. On the other hand,
E2 only decreases sGC b1 subunit through nuclear ER signaling
pathway. Considering that after 6 h, nuclear ER signaling pathway
is clearly predominant, therefore this time was chosen to study the
mechanisms involved in E2 effects on sGC subunits.
Mechanisms involved in E2 effects mediated by nuclear
ER: E2 actions on sGC subunits expression are dependent
on de novo transcription
Considering that a1 mRNA expression is significantly up-
regulated by E2 after 6 h, we investigate if the de novo transcription
of a1 is involved in such effect. To this end, pituitary cell cultures
were incubated with 2 mM actinomycin D (Act D), a transcription
Figure 3. E2 decreased sGC a1 mRNA expression in a PI3k-dependent pathway involving non-nuclear ER but does not modify sGC
b1 after 3 h of incubation. Pituitary cells in culture were incubated with vehicle (control) or 1 nM estrogen dendrimer conjugate (EDC), unable to
trespass cellular membrane for 3 h with or without 50 mM LY294002 (LY), a PI3K inhibitor, 30 min before treatment. mRNA expression was evaluated
by PCR. (A, B) Top, a representative PCRs. Bottom, Corresponding average densitometric values. Bars represent mean 6 SE of relative units
corresponding to a1 (open bars) and b1 (black bars) mRNA densitometric values normalized to b-actin, as percent of control (n=3). ANOVA followed
by Tukey’s test, *P,0.05, **P,0.01 vs. respective controls; #P,0.05, ###P,0.001 vs. EDC.
doi:10.1371/journal.pone.0029402.g003
Figure 4. E2 decreased sGC a1 protein expression in a PI3k-dependent pathway involving non-nuclear ER but does not modify sGC
b1 after 3 h of incubation. Pituitary cells in culture were incubated with vehicle (control) or 1 nM estrogen dendrimer conjugate (EDC), unable to
trespass cellular membrane for 3 h with or without 50 mM LY294002 (LY), a PI3K inhibitor, 30 min before treatment. Protein expression was evaluated
by western blot. (A, B) Top, representative western blots. Bottom, Corresponding average densitometric values. Bars represent mean 6 SE of a1
(open bars) and b1 (black bars) protein densitometric values normalized to b-actin, as percent of control (n=3). ANOVA followed by Tukey’s test,
*P,0.05 vs. respective controls; DDP,0.01 vs. E2; #P,0.05 vs. EDC.
doi:10.1371/journal.pone.0029402.g004
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that Act D had no effect per se on a1 and b1 mRNA expression but
was able to partially abolish E2-induced a1 increase (Figure 5A).
It is possible that E2 effects on a1 subunit exceed the inhibitory
activity of Act D at the dose studied. With regard to b1 subunit,
Act D did not block E2-induced b1 down-regulation. A similar
pattern was observed at the protein level by western blot
(Figure 5B). These results suggest that E2 effects on a1 expression
are dependent on de novo transcription.
E2 effects on sGC mRNA subunits expression are fully
dependent on de novo translation
E2 genomic actions typically involve both de novo transcription
and translation of certain factors. E2 effects on sGC mRNA
transcription could be mediated by different transcriptional
factors. To know whether E2 effects on sGC a1 and b1 mRNA
levels depend on de novo translation, anterior pituitary cell cultures
were preincubated with 10 mg/mL cycloheximide (CHX), a
protein synthesis inhibitor, 30 min before 1 nM E2 treatment.
After 6 h, total RNA was isolated and a1 and b1 sGC mRNA
expression was evaluated by PCR. CHX by itself had no effect on
sGC mRNAs expression, but, when co-administered with E2, was
able to fully abolish E2 effects on a1 and b1 mRNA levels
(Figure 6). This result shows that protein factors induced by E2
regulate mRNA levels of sGC subunits.
E2 promotes changes in the expression of factors that
regulates mRNA stabilization
It has been previously reported that both, a1 and b1 mRNAs
are able to bind AREs binding proteins that regulate their half-
lives in aortic tissue. One of the main AREs binding proteins is
HuR which has been shown to be involved in the regulation of
sGC mRNAs stabilization in other tissues [18]. AREs sequences
are also binding targets of other regulatory proteins, such as
AUF1. This protein is one of the main competitors with HuR for
binding to target mRNA elements. Four isoform proteins (p45,
p42, p40, and p37) of AUF1 are generated by alternative splicing
and upon binding to AREs, both AUF1p37 and AUF1p42
promote mRNAs destabilization, directing them to exosomes for
degradation [27]. Unlike AUF1p37, AUF1p42 includes exon 7.
On the other hand, AUF1p40 and AUF1p45 include an mRNA
stabilization domain in exon 2 [28]. However, it remains unknown
if AUF1 and HuR are expressed in pituitary and if there is a
functional relationship with E2 in anterior pituitary gland.
We first demonstrated, by PCR using specific primers, that
HuR (data not shown) and all exon 2- and exon 7-containing
AUF1 species (p45, p42 and p40) were constitutively expressed in
pituitary (Figure 7A). Then we investigate whether HuR and
AUF1 species are involved in E2-sGC mRNA regulation in
anterior pituitary. We show that 6 h of E2 treatment significantly
down-regulated HuR mRNA levels (Relative units (IOD) as % of
control; control: 10068, E2: 4365**, **P,0.01, Student’s t test)
whereas the expression of AUF1 species (p45, p42 and p40)
remained unchanged (Figure 7A). However, E2 increased AUF1
expression detected by primers directed to a conserved domain
among the four AUF1 isoforms (Figure 7B). Taking into account
that p45, p42 and p40 expression did not modify after E2
treatment, it can be stated that E2 induced an augment of p37
isoform.
The effects of nuclear and non-nuclear E2 pathways on HuR and
AUF1 expression were also addressed at earlier times. After 3 h of
treatment, neither free E2 nor EDC were able to significantly modify
HuR or AUF1p37 mRNA levels (data not shown).
Altogether, these results suggest that E2, by down-regulating
HuR mRNA levels and increasing p37 isoform, promotes an
environment of AREs-containing mRNAs destabilization in
anterior pituitary gland.
Discussion
Both subunits of sGC, a1 and b1, are constitutively expressed in
anterior pituitary gland. sGC is found in all hormone-producing
cells, while follicle-stellate cells are the only cell type lacking sGC
(unpublished data). The wide distribution of a1 and b1 in the
gland suggests the key role of sGC in the NO pathway in anterior
pituitary.
In this work we demonstrate that E2 modifies sGC a1 and b1
subunits expression in anterior pituitary gland through classical
and non classical pathway. Non-nuclear ER-dependent E2 actions
Figure 5. E2 actions on sGC subunits expression depended on de novo transcription. Pituitary cells in culture were incubated with vehicle
(control) or 1 nM E2 for 6 h with or without 2 mM actinomycin D (Act D), a transcription inhibitor, 30 min before treatment. (A), mRNA expression was
evaluated by PCR. Top, a representative PCR. Bottom, Average densitometric values. Bars represent mean 6 SE of relative units corresponding to a1
(open bars) and b1 (black bars) mRNA densitometric values normalized to b-actin, as percent of control (n=3). (B), protein expression was evalulated
by western blot. Top, a representative western blot. Bottom, Average densitometric values. Bars represent mean 6 SE of relative units corresponding
to a1 (open bars) and b1 (black bars) protein densitometric values normalized to b-actin, as percent of control (n=3). ANOVA followed by Tukey’s
test, *P,0.05, **P,0.01 vs. respective controls; DP,0.05 vs. E2.
doi:10.1371/journal.pone.0029402.g005
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exerts an opposite effect on a1 depending on the activated
pathway. E2 through non-nuclear ER, PI3k-dependent pathway
transiently decreases a1 subunit expression while through nuclear
ER pathway augments a1 levels. On the other hand, E2 only
modifies b1 subunit expression through nuclear ER. This evidence
could reveal a new level of regulation in NO/sGC pathway which
role in sGC regulation opens a new field of study with interesting
questions to be addressed.
It has been previously shown that E2 exerts a short- and long-
term decrease of sGC activity in anterior pituitary gland [5,29].
The non-nuclear actions of E2 could be of major importance in
the regulation of sGC activity at very short times, at the level of
membrane microdomains where sGC can also be found [30].
Thus E2 by decreasing a1 expression -the limiting subunit of sGC-
could be able to reduce cGMP production. Therefore, a1 levels
are first down-regulated probably due to the mRNA destabiliza-
tion environment promoted by E2 [31] but augmented later
through E2 stimulatory effect on a1 transcription. Even though
our results have showed that at short times the mRNA levels of
HuR and AUF1 remain unchanged, it cannot be ruled out that E2
through non-nuclear pathway could affect HuR and AUF1
activity and/or availability, which seems more likely as a rapid
E2 effect. Besides, it is also possible that other factors could be
involved in E2 non-nuclear actions. This topic opens a new field
which is currently under investigation.
On the other hand, at longer times E2 seems to down-regulate
sGC activity mainly by decreasing b1 expression, given that a1
increased levels are probably playing other role on cell physiology.
In that way, we have previously shown that a1 expression
positively correlated with proliferative stages of estrous cycle [6]
and its expression was found significantly augmented in pituitaries
of chronic-estrogenized female rats, although sGC activity is
diminished in both cases (unpublished data).
The E2 actions through nuclear and non-nuclear E2 pathways
could be of major relevance, not only on sGC regulation, but also
for many factors regulated by E2 in this gland. Up to date, the
paradoxical response to E2 depending on the pathway involved
was demonstrated only in bone [32]. Here, we provide the first
evidence that E2 nuclear and non-nuclear pathways trigger
different and opposite actions in anterior pituitary gland. We
demonstrate that E2-membrane effects on sGC expression that
take place at short times were transient and no longer evident after
6h .
We also studied the mechanisms by which E2 differentially
modifies a1 and b1 expression in anterior pituitary. We have
demonstrated that, after 6 h treatment, E2 actions on sGC
expression are mediated through activation of nuclear ER. Thus,
the regulation of sGC expression could happen mainly at
transcriptional/post-transcriptional levels. Our results show that
E2 regulation of a1 depends on both, de novo transcription and
translation while b1 expression depends only on de novo translation.
Once again, these findings support the hypothesis of independent
regulation of sGC subunits.
Figure 7. E2 treatment increases AUF1p37 mRNA expression in anterior pituitary gland. Pituitary cells in culture were incubated for 6 h
with vehicle (control) or with 1 nM E2. Exon 2 and exon 7 from AUF1 (A) or expression of a conservated domain of AUF1 (B) were evaluated by semi-
quantitative PCR. Top, a representative PCR. Bottom, average densitometric values. Bars represent mean 6 SE of relative units corresponding to
densitometric values of exon 2 and exon 7 (A) and AUF1 conservated domain (B) normalized to b-actin, expressed as percent of control (n=3).
Student’s ‘t’ test, **P,0.01 vs. control.
doi:10.1371/journal.pone.0029402.g007
Figure 6. E2 actions on sGC a1 and b1 mRNAs depended on de
novo translation. Pituitary cells in culture were incubated for 8 h with
vehicle (control) or 1 nM E2 with or without 10 mg/mL cycloheximide
(CHX), a translation inhibitor. mRNA expression was evaluated by
semiquantitative PCR. Top, A representative PCR. Bottom, average
densitomentric values. Bars represent mean 6 SE of relative units
corresponding to densitometric values of a1 (open bars) and b1 (black
bars) normalized to b-actin, expressed as percent of control (n=3).
ANOVA followed by Tukey’s test, **P,0.01 vs. respective controls;
DP,0.05, DDP,0.01 vs. E2.
doi:10.1371/journal.pone.0029402.g006
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affecting mRNA stability. As previously mentioned, adenine-uracil
rich elements (AREs) are involved in rapid mRNA degradation
and are binding targets of several proteins thus constituting
important elements for the regulation of genetic expression in
vertebrates. HuR protein binds to AREs [12] and protects mRNA
body from degradation. It has been showed that, at the post-
transcriptional level, HuR stabilizes a1 as well as b1 mRNAs and
actively protects them against degradation [18,33]. Here we
demonstrated that HuR is expressed normally in anterior pituitary
gland and is down-regulated after E2 acute treatment. On the
other hand, AUF1 protein is one of the main factors regulating
AREs-containing mRNA half-lives. Our results indicate that all
AUF1 isoforms are normally expressed in anterior pituitary and
that after E2 treatment only destabilizing isoform AUF1p37 is
augmented. This observation is in agreement with previous
evidence showing that E2 treatment was able to decrease the
expression of several proteins involved in mRNA stabilization in
anterior pituitary gland [30].
Both, a1 and b1 mRNAs yields AREs elements; however, they
are differentially affected by E2. Our results underline the
hypotheses that E2 affects b1 mRNA levels by stimulating the
expression of proteins involved in mRNA destabilization process-
es. The decrease of b1 levels after E2 treatment could be a
consequence of E2 actions on mRNA stabilization proteins. In that
way, a1 mRNA can also be target of degradation but, as
transcription is over enhanced, the global balance results in higher
a1 mRNA expression. Besides, it cannot be excluded that a1
mRNA could be protected from degradation through binding of
other factors or that other factors could be affecting a1 expression.
Genes of a1 and b1 subunits lack of estrogen response elements
(ERE) in their sequences, but they include consensus sites for
binding of Sp-1, c-Myb and NFk-B, among others, in their
promoter regions [34]. These factors are regulated by E2 [35-37]
so it could be possible that E2 regulates sGC subunit expression
through modulation of these proteins. Although sGC a1 and b1
promoter regions have many binding sites for different factors in
common, they yield independent activities, which together with
their separated location in the chromosome, support the
hypothesis of independent regulation of both genes [38]. These
facts could explain the differential response of both genes to E2
action [39].
Evidence provided by us, together with reports of temporal
unbalance in a1 and b1 expression [8] and participation of a1 and
b1 individually in cell cycle regulation [34,35] support the
hypotheses that the imbalance of sGC subunits expression exceed
the solely regulation of enzimatic sGC activity. It was previously
reported that a1 acts in prostate cancer via a novel pathway that
does not depend on b1 and that its expression correlates with
advanced prostate cancer. Thus, a1 has been proposed as an
important mediator of the procarcinogen effects of androgens
[34]. On the other hand, b1 was found associated with
chromosomes during mitosis in neural cells negatively regulating
cell cycle progression [35]. Thus, besides comprising sGC enzyme,
a1 and b1 independently appear as multifunctional proteins with
key roles in cell processes.
In summary, this work provides the first approach that both
sGC subunits are independently regulated and that E2 through
different mechanisms affects a1 and b1 sGC expression, which
strongly remarks the individual importance of sGC in processes
not related to cGMP synthesis in pituitary. This contributes to the
understanding of a1 and b1 roles in pituitary physiology which will
advance in future investigations.
Materials and Methods
Ethics Statement
All experimental procedures were approved by the Committee
on Ethics of the School of Medicine (University of Buenos Aires,
Resolution No. 1889/06) and were carried out in compliance with
the guidelines of the NIH Guide for the Care and Use of
Laboratory Animals.
Materials
Go Taq DNA polymerase, random hexamers and dNTPs were
provided by Promega (Madison, WI). TRIzol and molecular
biology reagents were from Invitrogen (Carlsbad, CA). Media and
reagents for cell culture were purchased from Gibco (Rockville,
MD, USA), except for the fetal bovine serum that was obtained
from GBO (Buenos Aires, Argentina). 17b-estradiol (E2), b-
estradiol 6-(O-carboxymethyl)oxime:BSA (E2-BSA), LY294002
and all other reagents and antibodies were obtained from Sigma
(St. Louis, MO). Estrogen dendrimer conjugate (EDC) was kindly
gifted by Dr. John A. Katzenellenbogen (University of Illinois at
Urbana-Champaign).
Preparation of E2-BSA free of E2
400 mL of E2-BSA (10
25 M estrogen dissolved in 50 mM Tris,
pH 8.5) was added to a centrifugal filter unit with a MW cut-off of
3,000 (Millipore) and centrifuged at 14,000 6 g until 50 mLo f
retentate remained. The retentate was washed 3 times with
350 mL of buffer, recovered and volume adjusted to 400 mL.
Animals and treatments
Adult female Wistar rats (180–200 g) were used at random
stages of estrous cycle. Animals were kept with controlled
conditions of light (12:12 h light/dark cycle) and temperature
(21–24 C). Food and water were supplied ad libitum.
Cell culture
Anterior pituitary glands (n=10) were removed within minutes
after decapitation. In females, anterior pituitary cell population is
composed by 52% lactotrophs, 20% somatotrophs, 10% gonad-
otrophs, 3% corticotrophs, 2% tirotrophs and 13% immunone-
gative cells [40]. Cells were obtained by enzymatic (trypsin/
DNAse) and mechanical dispersion (extrusion through a Pasteur
pipette) as previously described [5]. Cell viability was assessed by
the trypan blue exclusion method. In all cases, viability was higher
than 90%. Dispersed cells were seeded onto 24-well tissue culture
plates (1.10
6 cells/well) and stabilized for 48 h (37 C, 5% CO2 in
air) in phenol red-free Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% charcoal stripped fetal bovine
serum (CSFBS), 10 mL/mL MEM amino acids, 2 mM glutamine,
5.6 mg/mL amphotericin B and 25 mg/mL gentamicin (DMEM-
S-10% CSFBS).
Cell treatment
After the stabilization period (48 h), medium was changed for
fresh medium and cells were incubated during 3 or 6 h (37 C, 5%
CO2 in air) with 1 nM E2 or EDC. Control treatment was carried
out with complete culture media containing vehicle at the same
final concentration used for E2 (diluted in 1 nM ethanol) or EDC
treatments (diluted in 1 nM methanol). Different drugs were pre-
incubated for 30 min before E2 treatment, to avoid interactions
between E2 and drug kinetics. After treatment, RNA isolation or
protein extraction of each condition was carried out.
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177 mL of TRIzol reagent was added to each well. After
isolation, total RNA from tissues was spectrophotometrically
quantified at 260 nm. RNA integrity was checked in formalde-
hyde/formamide gel electrophoresis.
RT and PCR reactions
First strand cDNA was synthesized with Moloney murine
leukemia virus (M-MLV) reverse transcriptase in RT buffer
containing 5.5 mM MgCl2, 0.5 mM dNTP, 2.5 mM random
hexamers, and 3.125 U/mL M-MLV reverse transcriptase.
Reactions were done in a final volume of 12 mL containing 1 mg
RNA. The reverse transcription reaction was run at 37 C for
50 min and reverse transcriptase was inactivated by heating the
samples at 70 C for 15 min before the PCR reactions. To check
for genomic contamination, the same procedure was performed on
samples in a reaction solution lacking reverse transcriptase.
Specific primers for both subunits of sGC were designed from
published sequences [6] with Oligo Perfect designer software
(Invitrogen) and are detailed in Table 1. The amplified products
spanned from nucleotide position base 1971–2054 in the C-
terminal region of sGC a1 (GenBank accession number
NM_017090); from 714–823 in the N-terminal region of sGC
b1 (M22562); from 741–955 in the N-terminal region of HuR
(NM_001108848); from 649–674 in the middle region of
p45AUF1 (AB_046615), from 503–574 in the A cassette (N-
terminal region) of p45AUF1 and from 1077–1179 in the B
cassette (C-terminal region) of p45AUF1. b-actin (NM_031144)
was used as an endogenous control. Actin primers were designed
in order to detect amplification of DNA contamination. Then,
samples were thermocycled for PCR amplification (Mastercycler,
Eppendorf, Hamburg, Germany). The reaction mixture contained
GoTaq PCR buffer, 1.5 mM MgCl2, 200 mM of each dNTP,
0.625 U GoTaq polymerase and 300 nM of each primer. We
utilized RT-PCR methods to determine relative changes in
mRNA expression. Reactions were subjected to a varying number
(n=16–40) of cycles of PCR amplification (melting phase 94 C for
30 sec, annealing 55 C for 30 sec and extension 72 C for 1 min) to
find out the optimum cycle number within the linear range for
PCR amplification. Amplified products collected at various cycles
were analyzed by electrophoresis in 1.5% agarose-ethidium
bromide gels, and the optimum cycle number resulted to be 24
cycles for b-actin, 28 cycles for sGC a1 and sGC b1 and 40 cycles
for HuR and AUF1.
Analysis of semi-quantitative PCR data
The intensity of PCR products was determined by digital
image analysis using the Gel Pro Analyzer (Media Cybernetics,
LP, Silver Spring, MD) software for Windows. To allow statistical
comparison of results from different experiments, sGC subunits
levels were normalized to the value of the b-actin amplified band
in each lane.
Preparation of cell homogenates for immunoblot
analysis
Anterior pituitary cells in culture were tripsinized and sonicated
in lysis buffer containing 10 mM HEPES pH 7.4, 150 mM NaCl,
10 mM EDTA, 100 mM leupeptin, 350 mM pepstatin, 0.5 mM
PMSF and 0.2 mM DTT. Homogenates were centrifuged for
20 min at 10,000 x g (4 C) and the post-mitochondrial fraction was
used in the immunoblot analysis.
Protein measurement
Protein content of the supernatants was measured by Bradford
reagent, using bovine serum-albumin as standard.
Immunoblot analysis
Fifty micrograms of total protein from each sample was boiled
for 5 min in Laemmli sample buffer and fractioned on 10% SDS-
PAGE. Resolved proteins were transferred to polyvinylidene
difluoride membranes and blocked for 2 days at 4 C in blocking
buffer (TBS-0.05% Tween 20, 6% nonfat dry milk). Then,
membranes were co-incubated overnight at 4 C with rabbit
antisera anti-sGC a1 (1:1750) or b1 (1:700) subunits together with
anti-actin (1:1000) in blocking buffer. Blots were washed and
incubated for 1 h at room temperature with horseradish-
peroxidase conjugated goat antirabbit IgG (1:2000), followed by
detection of immunoreactivity with diaminobenzidine solution
containing 0.01% hydrogen peroxide.
Table 1. Primers used for semi-quantitative RT-PCR assays.
Gene Primers Product size (pb)
sGC a1 Forward 59-ACACAATATGCATCTCCGATGG-39 83
Reverse 59-GCTCTCTATACTCGCTTTGACCAA-39
sGC b1 Forward 59-CCCGTGGAAACTGATGTCAA-39 109
Reverse 59-CGGGACCTAGTAGTCACGCA-39
HuR Forward 59-TCGCAGCTGTACCACTCGCC-39 214
Reverse 59-CCAAACATCTGCCAGAGGATC-39
AUF1 Forward 59-GTAGACTGCACTCTGAAGTTAGATCC-39 450
Reverse 59-CTCCTCTAGATCCCCACTGCTG-39
AUF1 Exon 2 Forward 59-AGGATGAAGGCCATTCAAAC-39 71
Reverse 59- TTTTCCATTCTTCCCGCTG-39
AUF1 Exon 7 Forward 59-CCCCAGTCAAAACTGGAAC-39 102
Reverse 59-AGTCATATCCTCCATAACCACC-39
b-actin Forward 59-ACCACAGCTGAGAGGGAAATCG-39 276
Reverse 59-AGAGGTCTTTACGGATGTCAACG-39
doi:10.1371/journal.pone.0029402.t001
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The intensity of immunoblot signals was determined by digital
image analysis using Gel Pro Analyzer (Media Cybernetics, L.P.)
software for Windows. To allow statistical comparison of results
from different blots, levels were normalized to the value of the
actin immunoreactive band in each lane.
Statistical analysis
Results are expressed as mean 6 SE and evaluated by one-way
ANOVA followed by Tukey’s or Student’s t test, depending on the
experimental design. Differences between groups were considered
significant if P,0.05. Results were confirmed by at least three
independent experiments.
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